Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Small companies attempting to help solve a global crisis in drug-resistant infections with novel treatments are facing a wall ...

a All were multicenter, multinational, randomized trials. ITT = intention to treat, VAP = ventilator-associated pneumonia, cIAI = complicated intraabdominal infection, NR = not reported or not ...

In a new study published in the journal The Lancet, researchers have explored the possibility of treating acute, non-perforated appendicitis in children with antibiotics instead of surgery.

The groundbreaking clinical study showed that Zaynich treated seriously ill patients with infections caused by carbapenem-resistant (including meropenem-resistant) Gram-negative pathogens. These ...

That includes improving local data about co-morbidities that can affect the ability of antibiotics to work. Among the most important AMR targets are carbapenem-resistant bacteria. In Latin America ...

Shares of Wockhardt were in high demand on Monday after the company said that its drug Zaynich has achieved over 97 per cent clinical efficacy in treating critically ill patients with ...

Wockhardt's shares rose 4% on Monday, January 13, after the company said its drug Zaynich (WCK 5222) showed over 97% effectiveness in treating serious infections caused by carbapenem-resistant ...

Wockhardt Limited announced that its innovative antibiotic, Zaynich (Zidebactam/Cefepime), demonstrated over 97% clinical efficacy in treating serious infections ...

In this study, the team examined how nutrient stress might reveal novel approaches to treat bacterial infections that have shown resistance to the class of antibiotics called carbapenems. “Carbapenems ...

This marks significant progress in developing the first-of-its-kind oral carbapenem antibiotic for complicated urinary tract infections. Our cash runway into mid-2026 enables us to stay focused on ...